Rafferty Asset Management, LLC Nurix Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

$22.9 Billion
Q1 2025

A detailed history of Rafferty Asset Management, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 110,082 shares of NRIX stock, worth $1.15 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

110,082

Previous 116,186 5.25%

Holding current value

$1.15 Million

Previous $2.19 Million 40.27%

% of portfolio

0.01%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$11.88 - $20.15 $72,515 - $122,995	-6,104 Reduced 5.25%	110,082 $1.31 Million
Q4 2024 Feb 14, 2025	BUY	$18.64 - $28.14 $421,133 - $635,767	22,593 Added 24.14%	116,186 $2.19 Million
Q3 2024 Nov 13, 2024	SELL	$18.93 - $25.69 $827,676 - $1.12 Million	-43,723 Reduced 31.84%	93,593 $2.1 Million
Q2 2024 Aug 13, 2024	SELL	$12.02 - $21.3 $890,790 - $1.58 Million	-74,109 Reduced 35.05%	137,316 $2.87 Million
Q1 2024 May 13, 2024	BUY	$7.77 - $15.66 $1.64 Million - $3.31 Million	211,425 New	211,425 $3.11 Million
Q3 2023 Nov 13, 2023	SELL	$7.86 - $10.08 $123,001 - $157,741	-15,649 Reduced 13.67%	98,839 $776,000
Q2 2023 Aug 11, 2023	SELL	$8.7 - $13.28 $223,233 - $340,751	-25,659 Reduced 18.31%	114,488 $1.14 Million
Q1 2023 May 11, 2023	SELL	$8.56 - $13.26 $213,417 - $330,598	-24,932 Reduced 15.1%	140,147 $1.24 Million
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $336,916 - $498,540	34,170 Added 26.1%	165,079 $1.81 Million
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $738,073 - $1.19 Million	59,860 Added 84.25%	130,909 $1.71 Million
Q2 2022 Aug 12, 2022	SELL	$7.88 - $14.82 $592,820 - $1.11 Million	-75,231 Reduced 51.43%	71,049 $900,000
Q1 2022 May 13, 2022	BUY	$12.94 - $29.65 $719,127 - $1.65 Million	55,574 Added 61.27%	146,280 $2.05 Million
Q4 2021 Feb 10, 2022	BUY	$26.43 - $34.5 $841,531 - $1.1 Million	31,840 Added 54.09%	90,706 $2.63 Million
Q3 2021 Nov 10, 2021	SELL	$22.71 - $36.69 $450,203 - $727,342	-19,824 Reduced 25.19%	58,866 $1.76 Million
Q2 2021 Aug 10, 2021	BUY	$24.21 - $35.89 $262,993 - $389,873	10,863 Added 16.02%	78,690 $2.09 Million
Q1 2021 May 10, 2021	BUY	$26.98 - $50.17 $1.83 Million - $3.4 Million	67,827 New	67,827 $2.11 Million

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

75M

Call Options Held

56.9K

Put Options Held

7.9K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $493M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Nurix Therapeutics, Inc. Transaction History